CN112807256A - Whitening composition and application thereof in cosmetics - Google Patents
Whitening composition and application thereof in cosmetics Download PDFInfo
- Publication number
- CN112807256A CN112807256A CN202010207272.4A CN202010207272A CN112807256A CN 112807256 A CN112807256 A CN 112807256A CN 202010207272 A CN202010207272 A CN 202010207272A CN 112807256 A CN112807256 A CN 112807256A
- Authority
- CN
- China
- Prior art keywords
- parts
- melanin
- nonapeptide
- ethyl ether
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 54
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000000284 extract Substances 0.000 claims abstract description 37
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims abstract description 35
- 241000736199 Paeonia Species 0.000 claims abstract description 21
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 19
- 239000000654 additive Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000049 pigment Substances 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229940084032 paeonia lactiflora root extract Drugs 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 92
- 210000003491 skin Anatomy 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 18
- 210000003866 melanoblast Anatomy 0.000 abstract description 13
- 102000003425 Tyrosinase Human genes 0.000 abstract description 11
- 108060008724 Tyrosinase Proteins 0.000 abstract description 11
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 210000002752 melanocyte Anatomy 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 description 19
- 239000000523 sample Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 7
- 230000008099 melanin synthesis Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- PGNRLPTYNKQQDY-UHFFFAOYSA-N 2,3-dihydroxyindole Chemical compound C1=CC=C2C(O)=C(O)NC2=C1 PGNRLPTYNKQQDY-UHFFFAOYSA-N 0.000 description 6
- 230000003061 melanogenesis Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229940015975 1,2-hexanediol Drugs 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 4
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- 241001506047 Tremella Species 0.000 description 4
- 229960000458 allantoin Drugs 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008101 melanin synthesis pathway Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 2
- 101150015860 MC1R gene Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a whitening composition and application thereof in cosmetics, wherein the whitening composition consists of a peony root extract, VC ethyl ether and nonapeptide-1. The peony root extract can inhibit the activity of tyrosinase so as to inhibit the generation of melanin, nonapeptide-1 competitively binds with a receptor on a melanoblast cell to reduce the generation amount of melanin, and can play a role in homogenizing and improving the color, and the VC ethyl ether can reduce the ROS level in the melanocyte so as to achieve the purpose of reducing the formation of melanin. The whitening composition can inhibit melanin generation by combining radix Paeoniae extract, VC ethyl ether and nonapeptide-1, so as to produce 1+1+1 > 3 effect and whiten skin.
Description
Technical Field
The invention relates to the field of cosmetics, in particular to a whitening composition and application thereof in cosmetics.
Background
So-called "white clown", which is the pursuit of whitening by many women. In the market of skin care products, the demand of whitening is ever increasing, and the trend is more rising in recent years. Various whitening products are in endless, and the whitening market becomes a subdivided field of disputes between large brands at home and abroad. There are data showing that a product having whitening efficacy in 2016 accounts for about 1/7 in the overall sales of beauty products, and experts predict that the whitening market will be 660 billion in size every year in the future, and it can be said that whitening is an important market segment that keeps pace with moisturizing. Undeniably, the technology content and safety required by the special efficacy of whitening are higher than those required by other efficacies. Moreover, the cases related to the whitening failure of consumers in the market are endless, and how to safely and effectively whiten the skin is a serious topic in the skin care market.
The color of skin is controlled by various factors, mainly depending on the content and distribution of melanin. The melanin synthesis pathway is as follows: tyrosine is oxidized into dopaquinone, and is converted into melanin, namely excellent melanin or true melanin, after being continuously oxidized and decarboxylated into dihydroxyindole, which is the main component of skin pigment. Tyrosinase, an oxidoreductase, is the main rate-limiting enzyme in melanin synthesis, and the activity of tyrosinase determines the amount of melanin formation. Therefore, in order to inhibit melanin formation, the activity of tyrosinase is first inhibited to block a signal transduction pathway in the process of melanogenesis; secondly, alpha-melanotropin (alpha-MSH) is inhibited, the alpha-MSH enters the deep layer of the skin after being released and is combined with MC1R receptors on melanoblast cells, and once the alpha-MSH and the melanoblast cells are combined, a series of reactions in the melanoblast cells are directly activated to rapidly generate melanin; finally, by reducing the level of ROS in melanocytes, it is possible to prevent the activation of melanin synthesis, reduce or bind to intermediates in the melanogenesis process to block melanogenesis, block the polymerization of Dihydroxyindole (DHI) to melanin.
The radix Paeoniae extract can inhibit tyrosinase activity, thereby inhibiting melanin production.
Disclosure of Invention
Based on this, there is a need for a whitening composition containing an extract of paeonia lactiflora pall which can perform a whitening effect.
In addition, the application of the whitening composition in cosmetics is also needed to be provided.
A whitening composition, which consists of an extract of radix Paeoniae, VC ethyl ether and nonapeptide-1.
The whitening composition is applied to cosmetics.
A whitening cosmetic comprises radix Paeoniae extract, VC ethyl ether, nonapeptide-1, additive and water.
The peony root extract can inhibit the activity of tyrosinase so as to inhibit the generation of melanin, nonapeptide-1 competitively binds with a receptor on a melanoblast cell to reduce the generation amount of melanin, and can play a role in homogenizing and improving the color, and the VC ethyl ether can reduce the ROS level in the melanocyte so as to achieve the purpose of reducing the formation of melanin. The whitening composition can inhibit melanin generation by combining radix Paeoniae extract, VC ethyl ether and nonapeptide-1, so as to produce 1+1+1 > 3 effect and whiten skin.
Detailed Description
In order that the invention may be more fully understood, reference will now be made to the following description taken in conjunction with the accompanying drawings. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The application discloses a whitening composition, which consists of a peony root extract, VC ethyl ether and nonapeptide-1.
The melanin synthesis pathway is as follows: tyrosine is oxidized into dopaquinone, and is converted into melanin, namely excellent melanin or true melanin, after being continuously oxidized and decarboxylated into dihydroxyindole, which is the main component of skin pigment. Tyrosinase, an oxidoreductase, is the main rate-limiting enzyme in melanin synthesis, and the activity of tyrosinase determines the amount of melanin formation. Therefore, in order to inhibit melanin formation, the activity of tyrosinase is first inhibited to block a signal transduction pathway in the process of melanogenesis; secondly, alpha-melanotropin (alpha-MSH) is inhibited, the alpha-MSH enters the deep layer of the skin after being released and is combined with MC1R receptors on melanoblast cells, and once the alpha-MSH and the melanoblast cells are combined, a series of reactions in the melanoblast cells are directly activated to rapidly generate melanin; finally, by reducing the level of ROS in melanocytes, it is possible to prevent the activation of melanin synthesis, reduce or bind to intermediates in the melanogenesis process to block melanogenesis, block the polymerization of Dihydroxyindole (DHI) to melanin.
Radix Paeoniae extract can inhibit tyrosinase activity, thereby inhibiting melanin production.
Nonapeptide-1 is a biomimetic peptide, competitively binds with receptors on melanoblast cells, reduces melanin production, and can achieve the effects of homogenization and color improvement. Specifically, nonapeptide-1 acts on the MC1R gene outside a key target melanoblast cell to competitively antagonize the MC1R receptor, and when alpha-MSH reaches the extracellular binding site of the melanoblast cell, the site is found to be occupied by the nonapeptide-1, so that the aim of reducing the binding of the alpha-MSH and the MC1R is fulfilled, and the generation of melanin is inhibited.
VC ethyl ether can reduce melanin formation by reducing ROS levels in melanocytes.
Competitively binds with receptors on melanoblast cells, reduces the generation amount of melanin, and can achieve the effects of homogenization and color improvement. The VC ethyl ether can easily penetrate through the stratum corneum to enter the dermis, and is widely accepted by virtue of high-efficiency freckle removing and whitening effects.
The whitening composition can inhibit melanin generation by combining radix Paeoniae extract, VC ethyl ether and nonapeptide-1, so as to produce 1+1+1 > 3 effect and whiten skin.
Specifically, the whitening composition comprises the following components in parts by weight: 0.2 to 2 parts of peony root extract, 1 to 2 parts of VC ethyl ether and 2 to 5 parts of nonapeptide-1.
In a specific embodiment, the whitening composition comprises 0.4, 0.6, 0.8, 1, 1.2, 1.4, 1.6 or 1.8 parts of the paeonia lactiflora root extract by weight; the VC ethyl ether is 1.1 part, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts or 1.9 parts by weight; the mass portion of the nonapeptide-1 is 2.5, 3, 3.5, 4 or 4.5.
Preferably, when the whitening composition is used, the mass percentage concentration of the peony root extract is 0.2-2%, the mass percentage concentration of the VC ethyl ether is 1-2%, and the mass percentage concentration of the nonapeptide-1 is 2-5%.
Such a whitening composition can be applied to various fields, and in particular, it can be applied to cosmetics.
According to the regulations of the regulations on the supervision and control of cosmetics and hygiene, cosmetics refer to "daily chemical industry products for cleaning, removing bad smell, caring skin, beautifying and decorating by spreading any part (skin, hair, nails, lips, etc.) on the surface of human body by smearing, spraying or other similar methods".
Therefore, skin care products also belong to cosmetics.
Specifically, the cosmetic may be a facial mask liquid, skin lotion, essence, lotion, cream or makeup.
The application also discloses a whitening cosmetic which is composed of a peony root extract, VC ethyl ether, nonapeptide-1, an additive and water.
The peony root extract can inhibit the activity of tyrosinase so as to inhibit the generation of melanin, nonapeptide-1 competitively binds with a receptor on a melanoblast cell to reduce the generation amount of melanin, and can play a role in homogenizing and improving the color, and the VC ethyl ether can reduce the ROS level in the melanocyte so as to achieve the purpose of reducing the formation of melanin. The whitening composition can inhibit melanin generation by combining radix Paeoniae extract, VC ethyl ether and nonapeptide-1, so as to produce 1+1+1 > 3 effect and whiten skin.
The whitening cosmetic comprises the following components in parts by mass: 0.2 to 2 parts of peony root extract, 1 to 2 parts of VC ethyl ether, 2 to 5 parts of nonapeptide-1, additive and the balance of water.
In a specific embodiment, the part by mass of the paeonia lactiflora root extract in the whitening cosmetic is 0.4 part, 0.6 part, 0.8 part, 1 part, 1.2 parts, 1.4 parts, 1.6 parts or 1.8 parts; the VC ethyl ether is 1.1 part, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts or 1.9 parts by weight; the mass portion of the nonapeptide-1 is 2.5, 3, 3.5, 4 or 4.5.
The peony root extract is usually an alcohol extraction product.
In this embodiment, the paeonia radix extract is a paeonia radix extract. In other embodiments, other peony root extracts may be selected, for example, white peony root extract.
The additives are generally selected according to the actual product and determined in parts by mass.
The additive is a plurality of raw materials required by the production of cosmetics. Specifically, the additive may be at least one selected from the group consisting of a moisturizer, an oil, an antioxidant, a preservative, a sunscreen, a pigment, an adhesive and a perfume.
Taking the whitening cosmetic as the mask liquid as an example, the mass part of the additive can be 11 parts. At this time, the 11 parts of additives may be 3 parts of glycerin, 5 parts of butanediol, 0.08 part of xanthan gum, 0.1 part of tremella polysaccharide, 1.5 parts of betaine, 0.2 part of allantoin, 0.02 part of disodium EDTA, 0.1 part of arginine, 0.5 part of 1, 2-hexanediol, and 0.5 part of p-hydroxyacetophenone.
When the whitening cosmetic is a mask liquid, the preparation method comprises the following steps:
weighing various raw materials according to the mass parts, preparing glycerol, butanediol, xanthan gum and tremella polysaccharide into a solution, adding water, betaine, allantoin and EDTA disodium while stirring, heating to 80 ℃, stirring until the materials are uniformly dissolved, and keeping the temperature for 20 min;
cooling the mixed solution to about 45 ℃, sequentially adding the peony root extract, VC ethyl ether, nonapeptide-1, arginine, 1, 2-hexanediol and p-hydroxyacetophenone, and uniformly stirring;
and cooling the mixed solution to below 38 ℃ to obtain the facial mask solution.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Example 1: preparation of whitening mask liquid
The composition comprises, by weight, 100 parts of a total mass part, 0.5 part of a radix paeoniae rubra extract, 2 parts of nonapeptide-1, 1 part of VC ethyl ether, 3 parts of glycerol, 5 parts of butanediol, 0.08 part of xanthan gum, 0.1 part of tremella polysaccharide, 1.5 parts of betaine, 0.2 part of allantoin, 0.02 part of disodium EDTA, 0.1 part of arginine, 0.5 part of 1, 2-hexanediol, 0.5 part of p-hydroxyacetophenone and the balance of water.
Weighing various raw materials according to the mass parts, preparing glycerol, butanediol, xanthan gum and tremella polysaccharide into a solution, adding water, betaine, allantoin and EDTA disodium while stirring, heating to 80 ℃, stirring until the materials are uniformly dissolved, and keeping the temperature for 20 min;
cooling the mixed solution to about 45 ℃, sequentially adding the peony root extract, VC ethyl ether, nonapeptide-1, arginine, 1, 2-hexanediol and p-hydroxyacetophenone, and uniformly stirring;
and cooling the mixed solution to below 38 ℃ to obtain the whitening mask solution.
Example 2: preparation of whitening mask liquid
Example 2 differs from example 1 only in 1.2 parts of radix paeoniae rubra extract, 3 parts of nonapeptide-1, 1.5 parts of VC ethyl ether, and nothing else.
A whitening mask solution was prepared in the same manner as in example 1.
Example 3: preparation of whitening mask liquid
Example 3 differs from example 1 only in 2 parts of radix paeoniae rubra extract, 5 parts of nonapeptide-1, 2 parts of VC ethyl ether, and nothing else.
A whitening mask solution was prepared in the same manner as in example 1.
Example 4: melanin inhibition assay based on B16F10 cells
Raw materials and drugs
B16F10 cells, DPBS (doctor Deg), DMSO (Sigma), trypsin (Sigma), 70% alcohol, NaOH, radix Paeoniae Rubra extract (liquid, Shanghai nux Prinsepiae Xiye Co., Ltd.), VC ethyl ether (ringer technique), and nonapeptide-1 (Shanghai nux Prinsepiae Xiye Co., Ltd.).
Device
CO2Incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus)A micro-oscillator (Linbel), a microplate reader (BioTek), and a thermostat (Tester).
1) Preparation of a test sample: based on the cytotoxicity assay, efficacy assay concentrations were determined and corresponding samples were prepared according to table 1 below, using DMEM medium as the solvent.
Table 1: design of sample experiment
2) Cell culture: after digesting the B16F10 cells, the cells were dispersed in DMEM medium, counted in a Hemacytometer, and then diluted to a concentration of 5X 10 with DMEM4cells/mL. The diluted cell solutions were inoculated into 6-well plates, each containing 2mL of 1X 105cells/well. At 37 ℃ 5% CO2Was cultured in an incubator for 24 hours. After 24 hours of cell culture, the cells were observed for complete adherent growth, and if the cells were completely adherent, the original medium was removed and washed with DPBS.
3) Sample addition: after DPBS was removed, the samples prepared above were added separately, and after sample addition, the mixture was placed at 37 ℃ in 5% CO2Was cultured in an incubator for 48 hours.
4) Supernatant collection and testing: the medium was collected, centrifuged at 13500rpm for 10min, and the supernatant was taken to measure absorbance at a wavelength of 415 nm.
5) Melanin absorbance relationship test: preparing a melanin standard sample with the concentration of 1.0-100.0 ppm, and respectively testing the absorbance of the standard sample to obtain a curve of the concentration and the absorbance.
6) The absorbance values of the samples were taken into the above curves to obtain melanin contents in the culture media corresponding to different samples, as shown in table 2 below.
Table 2: melanin content in culture medium corresponding to different samples
As can be seen from Table 2, the control groups 1 to 3 and the sample groups 1 to 3 can both play a role in reducing melanin expression, and the sample groups 1 to 3 obviously have stronger melanin expression inhibition than the control groups 1 to 3. Therefore, the radix paeoniae alba extract, the VC ethyl ether and the nonapeptide-1 are combined for use, the three components synergistically inhibit the generation of melanin, and the effect that 1+1+1 is greater than 3 is achieved.
In addition, in sample groups 1-3, sample group 2 had the strongest inhibitory ability on melanin expression.
Example 5: evaluation of whitening efficacy
Test samples: test samples were prepared according to table 3 below, using purified water as the solvent.
Table 3: whitening efficacy evaluation test sample
The test principle is as follows: the change in Melanin content (Melanin Value) of the skin before and after sample application was measured.
Testing equipment: german CK multifunctional skin tester, model CK-MPA 10.
The testing steps are as follows:
before the experiment, the subject should agree to clean the forearm of both hands, measure the forearm and wipe it clean with dry tissue. After cleaning, the inner forearm of the test subject is marked with a measuring area. Before formal test, sitting still in a room meeting the standard for at least 30min, no drinking water, exposing forearms, placing in a test state, and keeping relaxed.
The inner side of the left and right arms in the experiment is marked with 3 multiplied by 3cm2In the test area, the same arm can mark a plurality of areas, and the areas are spaced by 1 cm. Both the test product and the placebo were randomly distributed on the left and right arms. Melanin assay of test and control areas using a melanin probe-analyzerAmount of the compound (A). Each area was assayed 15 times in parallel. The blank value of each test area was measured and then measured at 2.0. + -. 0.1mg sample/cm2The test was evenly spread into the test area using a latex finger cot. After 30 minutes, the melanin value of the area was measured using a melanin probe, and the data was recorded.
The melanin content of the product in each area before and after use every day is respectively measured according to the experimental design, and the change of the melanin is calculated by comparing the initial values.
The experimental results are as follows: the skin melanin content changes are shown in table 4 below.
Table 4: changes in skin melanin content
As can be seen from Table 4, the control groups 1 to 3 and the sample groups 1 to 3 can both play a role in reducing the melanin content of the skin, and the effect of the sample groups 1 to 3 is obviously stronger than that of the control groups 1 to 3. Therefore, by combining the peony root extract, the VC ethyl ether and the nonapeptide-1, the three components can be used for inhibiting the generation of melanin and reducing the content of the melanin in the skin under the synergistic action, so that the effect of 1+1+1 > 3 is achieved.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the claims. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A whitening composition is characterized by consisting of a peony root extract, VC ethyl ether and nonapeptide-1.
2. The whitening composition according to claim 1, which consists of the following components in parts by mass: 0.2 to 2 parts of peony root extract, 1 to 2 parts of VC ethyl ether and 2 to 5 parts of nonapeptide-1.
3. The whitening composition of claim 2, wherein the paeonia lactiflora root extract is present in an amount of 0.4 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.4 parts, 1.6 parts, or 1.8 parts by mass;
the VC ethyl ether is 1.1 part, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts or 1.9 parts by weight;
the mass portion of the nonapeptide-1 is 2.5, 3, 3.5, 4 or 4.5.
4. The whitening composition according to any one of claims 1 to 3, wherein when the whitening composition is used, the concentration by mass of the radix paeoniae alba extract is 0.2-2%, the concentration by mass of the VC ethyl ether is 1-2%, and the concentration by mass of the nonapeptide-1 is 2-5%.
5. Use of the whitening composition according to any one of claims 1 to 4 in cosmetics.
6. The use according to claim 5, wherein the cosmetic product is a facial mask solution, a skin lotion, a serum, an emulsion, a cream or a makeup.
7. A whitening cosmetic is characterized by comprising a peony root extract, VC ethyl ether, nonapeptide-1, an additive and water.
8. The whitening cosmetic of claim 7, wherein each hundred parts of the whitening cosmetic consists of, in parts by mass: 0.2 to 2 parts of peony root extract, 1 to 2 parts of VC ethyl ether, 2 to 5 parts of nonapeptide-1, additive and the balance of water.
9. The whitening cosmetic of claim 8, wherein the peony root extract is present in an amount of 0.4 parts, 0.6 parts, 0.8 parts, 1 part, 1.2 parts, 1.4 parts, 1.6 parts, or 1.8 parts by mass;
the VC ethyl ether is 1.1 part, 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts or 1.9 parts by weight;
the mass portion of the nonapeptide-1 is 2.5, 3, 3.5, 4 or 4.5.
10. The whitening cosmetic of claim 8, wherein the additive is at least one selected from the group consisting of a moisturizer, an oil, an antioxidant, a preservative, a sunscreen, a pigment, an adhesive and a perfume.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010207272.4A CN112807256A (en) | 2020-03-23 | 2020-03-23 | Whitening composition and application thereof in cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010207272.4A CN112807256A (en) | 2020-03-23 | 2020-03-23 | Whitening composition and application thereof in cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112807256A true CN112807256A (en) | 2021-05-18 |
Family
ID=75853309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010207272.4A Pending CN112807256A (en) | 2020-03-23 | 2020-03-23 | Whitening composition and application thereof in cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112807256A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005029494A (en) * | 2003-07-10 | 2005-02-03 | Fancl Corp | Melanocyte proliferation inhibitor and cosmetic containing the same |
| CN105662959A (en) * | 2016-02-03 | 2016-06-15 | 上海新高姿化妆品有限公司 | Natural plant composition with skin whitening effect and application thereof to cosmetics |
| WO2016115283A2 (en) * | 2015-01-13 | 2016-07-21 | University Of Washington Through Its Center For Commercialization | Reagents and methods for whitening teeth |
| CN107224412A (en) * | 2016-03-23 | 2017-10-03 | 欧诗漫生物股份有限公司 | A kind of cosmetics whitening emulsion and preparation method thereof |
| CN108066245A (en) * | 2018-02-09 | 2018-05-25 | 广州御延堂生物科技有限公司 | A kind of skin whitening, moisturizing stoste and preparation method thereof |
| CN108542819A (en) * | 2018-05-25 | 2018-09-18 | 深圳市佑惑生物科技有限公司 | A kind of biology skin lightening facial mask liquid and preparation method thereof |
| CN109157429A (en) * | 2018-09-20 | 2019-01-08 | 深圳市维琪医药研发有限公司 | A kind of active peptides and tyrosinase inhibitor composition for whitening spot-removing |
-
2020
- 2020-03-23 CN CN202010207272.4A patent/CN112807256A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005029494A (en) * | 2003-07-10 | 2005-02-03 | Fancl Corp | Melanocyte proliferation inhibitor and cosmetic containing the same |
| WO2016115283A2 (en) * | 2015-01-13 | 2016-07-21 | University Of Washington Through Its Center For Commercialization | Reagents and methods for whitening teeth |
| CN105662959A (en) * | 2016-02-03 | 2016-06-15 | 上海新高姿化妆品有限公司 | Natural plant composition with skin whitening effect and application thereof to cosmetics |
| CN107224412A (en) * | 2016-03-23 | 2017-10-03 | 欧诗漫生物股份有限公司 | A kind of cosmetics whitening emulsion and preparation method thereof |
| CN108066245A (en) * | 2018-02-09 | 2018-05-25 | 广州御延堂生物科技有限公司 | A kind of skin whitening, moisturizing stoste and preparation method thereof |
| CN108542819A (en) * | 2018-05-25 | 2018-09-18 | 深圳市佑惑生物科技有限公司 | A kind of biology skin lightening facial mask liquid and preparation method thereof |
| CN109157429A (en) * | 2018-09-20 | 2019-01-08 | 深圳市维琪医药研发有限公司 | A kind of active peptides and tyrosinase inhibitor composition for whitening spot-removing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2613121C2 (en) | Cosmetic composition | |
| US9770404B2 (en) | Cosmetic composition for whitening and improving the resilience of skin | |
| CN108014045B (en) | Man skin care composition and application thereof | |
| KR20140012054A (en) | Multi-purpose cosmetic compositions | |
| WO1999002128A1 (en) | A skin care and protection composition and a method for preparation thereof | |
| CN108125803A (en) | A kind of whitening spot-eliminating composition | |
| CN107595756A (en) | A kind of whitening is dispelled black compound | |
| KR20220163424A (en) | Low-pH skin care composition and method of use thereof | |
| MX2011001298A (en) | Skin lightening compositions comprising co2 extracts. | |
| KR101860109B1 (en) | Skin external composition containing floral ginsenoside | |
| KR20080026800A (en) | Cosmetic composition | |
| KR101985356B1 (en) | Composition for skin external application containing fermented soybean extract | |
| KR20070083302A (en) | Composition for inhibiting collagen degradation and promoting collagen synthesis comprising emodin | |
| KR101685579B1 (en) | Method for manufacturing skin-whitener composition containing Thuja orientalis and skin-whitener composition prepared therefrom | |
| KR101744889B1 (en) | Composition for Anti-oxidation, Whitening and Wrinkles protection | |
| KR20080030773A (en) | Cosmetic composition for anti-wrinkle | |
| CN112807256A (en) | Whitening composition and application thereof in cosmetics | |
| Shaikh et al. | A Review on Anti-ageing and Whitening effect | |
| CN113116753B (en) | Rose essential oil face cream and preparation method thereof | |
| CN108272677A (en) | A kind of moistening and whitening facial mask and preparation method thereof containing plant extracts | |
| KR101781111B1 (en) | Cosmetic composition containing extracts of magnolia officinalis, buplerum falcatum and/or schizonepeta tenuifolia | |
| KR100738434B1 (en) | Cosmetic composition containing pyrrolidinyl diaminopyrimidine oxide | |
| KR20030037446A (en) | Skin care cosmetics containing Prunus mume extracts | |
| JP7289833B2 (en) | Cosmetic use of plant Elephant extract (Phytelephas sp.) | |
| KR20130115566A (en) | Cosmetic composition from cephalopod extract and its fermentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210518 |